AR064494A1 - Variantes de lipasa para uso farmaceutico - Google Patents

Variantes de lipasa para uso farmaceutico

Info

Publication number
AR064494A1
AR064494A1 ARP070105859A ARP070105859A AR064494A1 AR 064494 A1 AR064494 A1 AR 064494A1 AR P070105859 A ARP070105859 A AR P070105859A AR P070105859 A ARP070105859 A AR P070105859A AR 064494 A1 AR064494 A1 AR 064494A1
Authority
AR
Argentina
Prior art keywords
lipases
lipase
pharmaceutical use
protease
diabetes
Prior art date
Application number
ARP070105859A
Other languages
English (en)
Spanish (es)
Original Assignee
Novozymes As
Novozymes Biotech Inc
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As, Novozymes Biotech Inc, Solvay Pharm Gmbh filed Critical Novozymes As
Publication of AR064494A1 publication Critical patent/AR064494A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ARP070105859A 2006-12-21 2007-12-21 Variantes de lipasa para uso farmaceutico AR064494A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87119606P 2006-12-21 2006-12-21

Publications (1)

Publication Number Publication Date
AR064494A1 true AR064494A1 (es) 2009-04-08

Family

ID=38043020

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105859A AR064494A1 (es) 2006-12-21 2007-12-21 Variantes de lipasa para uso farmaceutico

Country Status (16)

Country Link
US (3) US8273348B2 (cg-RX-API-DMAC7.html)
EP (6) EP2455460A3 (cg-RX-API-DMAC7.html)
JP (1) JP5406040B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090101930A (cg-RX-API-DMAC7.html)
CN (2) CN101743308B (cg-RX-API-DMAC7.html)
AR (1) AR064494A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007337150A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0721103A2 (cg-RX-API-DMAC7.html)
CA (3) CA2670643C (cg-RX-API-DMAC7.html)
IL (1) IL198893A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009006597A (cg-RX-API-DMAC7.html)
NO (1) NO20092729L (cg-RX-API-DMAC7.html)
RU (1) RU2009128067A (cg-RX-API-DMAC7.html)
TW (1) TW200829698A (cg-RX-API-DMAC7.html)
WO (1) WO2008079685A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200903598B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2381813C2 (ru) 2004-03-22 2010-02-20 Зольвай Фармасьютиклз Гмбх Пероральные фармацевтические композиции на основе продуктов, содержащих липазы, прежде всего панкреатин, и пав
CA2616943C (en) 2005-07-29 2016-04-12 Solvay Pharmaceuticals Gmbh Processes for the manufacture of sterilized pancreatin powder
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2455460A3 (en) * 2006-12-21 2012-12-26 Novozymes A/S Lipase variants for pharmaceutical use
EP2250258B1 (en) * 2008-02-29 2017-01-04 Novozymes A/S Lipolytic enzyme variant with improved stability and polynucleotides encoding same
JP2011513539A (ja) * 2008-02-29 2011-04-28 ザ プロクター アンド ギャンブル カンパニー リパーゼを含む洗剤組成物
DK2254996T3 (da) 2008-02-29 2013-10-07 Dsm Ip Assets Bv Lipaser med høj specificitet for kortkædede fedtsyrer og anvendelser deraf
WO2011072117A1 (en) 2009-12-09 2011-06-16 The Procter & Gamble Company Fabric and home care products
CN109022518A (zh) 2011-07-22 2018-12-18 诺维信北美公司 用于预处理纤维素材料和改进其水解的方法
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
CN110777016A (zh) * 2011-12-29 2020-02-11 诺维信公司 具有脂肪酶变体的洗涤剂组合物
CN108148823B (zh) * 2012-02-03 2023-03-14 诺维信公司 脂肪酶变体以及编码它们的多核苷酸
EP2834353B1 (en) * 2012-04-02 2017-07-19 Novozymes A/S Lipase variants and polynucleotides encoding same
EP2906691B1 (en) * 2012-10-12 2021-01-27 Danisco US Inc. Compositions and methods comprising a lipolytic enzyme variant
MX392247B (es) 2013-05-14 2025-03-24 Novozymes As Composiciones detergentes.
EP3022299B1 (en) * 2013-07-19 2020-03-18 Danisco US Inc. Compositions and methods comprising a lipolytic enzyme variant
CN107075489A (zh) * 2014-11-20 2017-08-18 诺维信公司 脂环酸芽孢杆菌变体以及编码它们的多核苷酸
EP4067485A3 (en) * 2014-12-05 2023-01-04 Novozymes A/S Lipase variants and polynucleotides encoding same
EP3230442B1 (en) * 2014-12-09 2019-05-22 Novozymes A/S Lipase variants and polynucleotides encoding same
US20180355404A1 (en) 2015-04-07 2018-12-13 Novozymes A/S Methods for selecting enzymes having lipase activity
EP3929285A3 (en) * 2015-07-01 2022-05-25 Novozymes A/S Methods of reducing odor
WO2017005640A1 (en) * 2015-07-03 2017-01-12 Novozymes A/S Detergent compositions with improved stability in the presence of sulfites
US11326152B2 (en) * 2016-07-18 2022-05-10 Novozymes A/S Lipase variants, polynucleotides encoding same and the use thereof
CN110462037A (zh) * 2017-01-30 2019-11-15 学校法人日本医科大学 腺相关病毒(aav)衣壳蛋白的突变体
US11286443B2 (en) * 2017-09-27 2022-03-29 The Procter & Gamble Company Detergent compositions comprising lipases
CA3073362A1 (en) 2017-09-27 2019-04-04 Novozymes A/S Lipase variants and microcapsule compositions comprising such lipase variants
CN111801416A (zh) * 2018-02-08 2020-10-20 诺维信公司 脂肪酶变体及其组合物
US12269847B2 (en) * 2018-08-16 2025-04-08 Donaldson Company, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
CN111334369B (zh) * 2020-03-11 2022-10-21 陕西科技大学 一种酶法制备卵磷脂型pufa的方法
EP4172325A1 (en) * 2020-06-24 2023-05-03 Cilian AG New lipase enzyme
US20240035005A1 (en) * 2020-10-29 2024-02-01 Novozymes A/S Lipase variants and compositions comprising such lipase variants
CN113846074B (zh) * 2021-10-20 2022-10-21 南京林业大学 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用
US20250311734A1 (en) 2022-05-14 2025-10-09 Novozymes A/S Compositions and Methods for Preventing, Treating, Suppressing and/or Eliminatting Phytopathogenic Infestations and Infections
CN119522274A (zh) * 2022-06-24 2025-02-25 诺维信公司 脂肪酶变体和包含这样的脂肪酶变体的组合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
AU657278B2 (en) 1990-09-13 1995-03-09 Novo Nordisk A/S Lipase variants
DK46693D0 (cg-RX-API-DMAC7.html) * 1993-04-23 1993-04-23 Novo Nordisk As
US5869438A (en) 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
WO1992010755A1 (en) 1990-12-05 1992-06-25 Novo Nordisk A/S Proteins with changed epitopes and methods for the production thereof
EP0585285B1 (en) 1991-05-01 1998-08-12 Novo Nordisk A/S Stabilized enzymes
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
BR9407752A (pt) 1993-10-04 1997-03-04 Novo Nordisk As Preparaçao de enzima aditivo detergente composiçao detergente processo para o tratamento de fibras lignocelulósicas
AU1806795A (en) * 1994-02-22 1995-09-04 Novo Nordisk A/S A method of preparing a variant of a lipolytic enzyme
EP0793726A1 (en) 1994-11-24 1997-09-10 Novo Nordisk A/S A process for producing polypeptides with reduced allergenicity
FI972443L (fi) 1994-12-07 1997-06-09 Novo Nordisk As Polypeptidi, jonka allergeenisuus on vähentynyt
CA2209617C (en) 1995-01-26 2002-05-28 Novo Nordisk A/S Animal feed additives comprising xylanase
US6495357B1 (en) * 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
ATE282087T1 (de) 1995-07-14 2004-11-15 Novozymes As Modifiziertes enzym mit lipolytischer aktivität
ATE267248T1 (de) 1995-08-11 2004-06-15 Novozymes As Neuartige lipolytische enzyme
EP0954572A1 (en) 1997-01-10 1999-11-10 Novo Nordisk A/S Enzyme coupled with polymeric molecules for skin care
AU740207B2 (en) 1997-02-06 2001-11-01 Novozymes A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
DK1002064T3 (da) 1997-06-25 2008-02-04 Novozymes As Modificeret polypeptid
ATE328070T1 (de) * 1998-02-17 2006-06-15 Novozymes As Lipasevariante
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
JP2002527059A (ja) 1998-10-13 2002-08-27 ノボザイムス アクティーゼルスカブ 低められた免疫応答を有する修飾されたポリペプチド
CA2348938A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Low allergenic protein variants
ATE365210T1 (de) * 1998-10-30 2007-07-15 Novozymes As Glykosylierte proteine mit reduzierter allergenität
US7312062B2 (en) * 1998-11-27 2007-12-25 Novozymes A/S Lipolytic enzyme variants
WO2000032758A1 (en) 1998-11-27 2000-06-08 Novozymes A/S Lipolytic enzyme variants
ES2194720T3 (es) 1999-03-17 2003-12-01 Solvay Pharm Gmbh Enzimas para el tratamiento de diabetes mellitus tipo i.
MXPA01009700A (es) * 1999-03-31 2002-05-14 Novo Nordisk As Variante de lipasa.
DK1428874T3 (en) * 1999-03-31 2014-03-10 Novozymes As lipase variant
WO2001058275A2 (en) 2000-02-08 2001-08-16 F Hoffmann-La Roche Ag Use of acid-stable subtilisin proteases in animal feed
EP2258852A1 (en) * 2000-04-28 2010-12-08 Novozymes A/S Lipolytic enzyme variant
ES2323947T3 (es) * 2001-01-10 2009-07-28 Novozymes A/S Variante de enzima lipolitica.
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
EP1360278B1 (en) 2001-02-07 2009-09-23 Novozymes A/S Lipase variants
AU2003203139B2 (en) * 2002-01-16 2007-11-08 Novozymes A/S Lipolytic enzyme variants and method for their production
AU2004208860A1 (en) 2003-02-06 2004-08-19 Novozymes A/S Human heavy chain antibody expression in filamentous fungi
CA2523400C (en) * 2003-05-09 2015-03-17 Novozymes A/S Variant lipolytic enzymes
WO2004111224A1 (en) 2003-06-19 2004-12-23 Novozymes A/S Improved proteases and methods for producing them
US20060251763A1 (en) 2003-06-19 2006-11-09 Patkar Shamkant A Phospholipase variants
AR047440A1 (es) 2004-01-21 2006-01-18 Novozymes As Produccion de un anticuerpo monoclonal en un hongo heterocarion o una celula huesped fungal
RU2381813C2 (ru) 2004-03-22 2010-02-20 Зольвай Фармасьютиклз Гмбх Пероральные фармацевтические композиции на основе продуктов, содержащих липазы, прежде всего панкреатин, и пав
DE602005022471D1 (de) 2004-10-14 2010-09-02 Altus Pharmaceuticals Inc Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz
US20080138856A1 (en) 2005-02-10 2008-06-12 Novozymes A/S Enzymatic Enantioselective Ester or Amide Hydrolysis or Synthesis
MX2007015472A (es) * 2005-06-24 2008-04-17 Novozymes As Lipasas para uso farmaceutico.
CA2612811A1 (en) 2005-06-24 2006-12-28 Novozymes A/S Amylases for pharmaceutical use
AU2006261443A1 (en) 2005-06-24 2006-12-28 Novozymes A/S Proteases for pharmaceutical use
WO2007080197A2 (en) * 2006-01-16 2007-07-19 Novozymes A/S Immobilised enzymes
AR059154A1 (es) * 2006-01-23 2008-03-12 Procter & Gamble Una composicion que comprende una lipasa y un catalizador de blanqueador
BRPI0707202A2 (pt) * 2006-01-23 2011-04-26 Novozymes Inc variante, seqüência de dna, vetor de expresseão, célula hospedeira transformada, e, método de produzir uma variante de lìpase
EP2455460A3 (en) * 2006-12-21 2012-12-26 Novozymes A/S Lipase variants for pharmaceutical use

Also Published As

Publication number Publication date
US20120308543A1 (en) 2012-12-06
ZA200903598B (en) 2010-04-28
EP2455459A2 (en) 2012-05-23
AU2007337150A1 (en) 2008-07-03
CN101743308B (zh) 2015-09-16
EP2455462A2 (en) 2012-05-23
NO20092729L (no) 2009-09-18
EP2261328A1 (en) 2010-12-15
CA3081308A1 (en) 2008-07-03
JP5406040B2 (ja) 2014-02-05
US20100034797A1 (en) 2010-02-11
CN105112386A (zh) 2015-12-02
CA2670643A1 (en) 2008-07-03
EP2455462B1 (en) 2016-03-16
EP2455459A3 (en) 2013-04-24
CA2961041A1 (en) 2008-07-03
CA2670643C (en) 2017-04-25
EP2455459B1 (en) 2016-03-16
CN101743308A (zh) 2010-06-16
EP2455460A2 (en) 2012-05-23
KR20090101930A (ko) 2009-09-29
EP2455461A2 (en) 2012-05-23
US9029115B2 (en) 2015-05-12
EP2455461A3 (en) 2013-05-29
EP2455462A3 (en) 2013-05-29
EP2455461B1 (en) 2016-03-16
IL198893A0 (en) 2010-02-17
RU2009128067A (ru) 2011-01-27
EP2099907A2 (en) 2009-09-16
EP2261328B1 (en) 2013-11-20
BRPI0721103A2 (pt) 2014-03-04
WO2008079685A2 (en) 2008-07-03
WO2008079685A3 (en) 2008-11-06
TW200829698A (en) 2008-07-16
JP2010512795A (ja) 2010-04-30
CA2961041C (en) 2020-07-14
CA3081308C (en) 2024-02-20
US9539311B2 (en) 2017-01-10
MX2009006597A (es) 2009-07-02
US20150209414A1 (en) 2015-07-30
EP2455460A3 (en) 2012-12-26
US8273348B2 (en) 2012-09-25

Similar Documents

Publication Publication Date Title
AR064494A1 (es) Variantes de lipasa para uso farmaceutico
AR053634A1 (es) Lipasas para uso farmaceutico
Pernow et al. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?
Petrosino et al. N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities
BRPI0510817A (pt) protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença
ES2572160T3 (es) Una nueva preparación farmacéutica para preeclampsia
Shen et al. Mutational analysis of structural features of rat hormone-sensitive lipase
AR032392A1 (es) Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
AR119552A2 (es) Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
Paula et al. Modulation of the peroxiredoxin system by cytokines in insulin-producing RINm5F cells: down-regulation of PRDX6 increases susceptibility of beta cells to oxidative stress
ECSP088758A (es) Métodos para reducir la aglomeración de proteína
EP4241854A3 (en) Lysosomal storage disease enzyme
JP2010512795A5 (cg-RX-API-DMAC7.html)
WO2005111008A3 (en) Compounds for enzyme inhibition
GB2497715A (en) Preparation and use of combination enzyme and gastriontestinal modulator delivery systems
AR063570A1 (es) Efectos biologicos mejorados para composiciones que comprenden acido rosmarinico
BR112012000914B8 (pt) uso de polipeptídeo com atividade condrogênica, método in vitro de indução da diferenciação de células-tronco mesenquimais em condrócitos, e composição farmacêutica para aplicação intra-articular
MX2015000760A (es) Sistema de suministro de farmaco gastro - retentivo.
Bhatta et al. Angiotensin II-induced arterial thickening, fibrosis and stiffening involves elevated arginase function
BRPI0922653B8 (pt) uso de uma lipase bacteriana do tipo pseudomonas em solução aquosa
Gidlöf Toward a new paradigm for targeted natriuretic peptide enhancement in heart failure
AR078291A1 (es) Composiciones de enzimas pancreaticas y metodos para tratar pancreatitis e insuficiencia pancreatica
MX2010005690A (es) Variantes de proteasa para uso farmaceutico.
Xiao et al. The protein kinase C cascade regulates recruitment of matrix metalloprotease 9 to podosomes and its release and activation
WO2006136160A3 (en) Proteases for pharmaceutical use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal